Search Results: PARP

We’ve helped double brain tumour survival over the past 40 years. Now, researchers are combining some of our most successful drugs, temozolomide and PARP inhibitors, to make glioblastoma treatment more effective.

As our 20th anniversary year draws to a close, we’re celebrating some of the pioneering women who have contributed to impactful cancer research and paved the way for even more.

This year has been full of research, advances and people worth celebrating. Here are some of our biggest stories from the past 12 months. 

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

Recently, news of a COVID-19 vaccine has dominated headlines. We’ve summarised all the information that is out there, with rolling updates, in our new vaccine blog post.

We spoke to Professor Andrew Tutt about how you build a successful scientific team, the importance of translation and why you always need a touch of humbleness…

Cancer Research Matters provokes conversation around cancer science, how it shapes our understanding of the disease and the challenges we face as we develop therapies

To mark 20 years since the merger of the Cancer Research Campaign and the Imperial Cancer Research Fund, we’ve delved into the research of the charities’ that led to many of the drugs in use today.

Cancer Research Matters provokes conversation around cancer science, how it shapes our understanding of the disease and the challenges we face as we develop therapies.

Chief scientist Karen Vousden, contemplates the advances coming from cell biology and genomics and why the new frontiers of cancer research require a systems biology approach.